Literature DB >> 31712777

Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.

Maximilian Merz1, Thomas Hielscher2, David Schult3, Elias K Mai3, Marc S Raab3,4, Jens Hillengass3,5, Anja Seckinger3, Dirk Hose3, Martin Granzow6, Anna Jauch6, Hartmut Goldschmidt3,7.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31712777      PMCID： PMC7214236          DOI： 10.1038/s41375-019-0634-2

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.

Authors:  Niels Weinhold; Desiree Kirn; Anja Seckinger; Thomas Hielscher; Martin Granzow; Uta Bertsch; Gerlinde Egerer; Hans Salwender; Igor W Blau; Katja Weisel; Jens Hillengass; Marc S Raab; Dirk Hose; Hartmut Goldschmidt; Anna Jauch
Journal:  Haematologica       Date:  2015-11-26       Impact factor: 9.941

2.  Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Authors:  Tilmann Bochtler; Maximilian Merz; Thomas Hielscher; Martin Granzow; Korbinian Hoffmann; Alwin Krämer; Marc-Steffen Raab; Jens Hillengass; Anja Seckinger; Christoph Kimmich; Tobias Dittrich; Carsten Müller-Tidow; Dirk Hose; Hartmut Goldschmidt; Ute Hegenbart; Anna Jauch; Stefan O Schönland
Journal:  Blood Adv       Date:  2018-10-23

3.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

4.  Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

Authors:  Kai Neben; Anna Jauch; Thomas Hielscher; Jens Hillengass; Nicola Lehners; Anja Seckinger; Martin Granzow; Marc S Raab; Anthony D Ho; Hartmut Goldschmidt; Dirk Hose
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544

Review 5.  Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma.

Authors:  David González; Mirjam van der Burg; Ramón García-Sanz; James A Fenton; Anton W Langerak; Marcos González; Jacques J M van Dongen; Jesus F San Miguel; Gareth J Morgan
Journal:  Blood       Date:  2007-07-18       Impact factor: 22.113

6.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.

Authors:  S V Rajkumar; V Gupta; R Fonseca; A Dispenzieri; W I Gonsalves; D Larson; R P Ketterling; J A Lust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2013-03-21       Impact factor: 11.528

7.  Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Authors:  Maximilian Merz; Anna Jauch; Thomas Hielscher; Tilmann Bochtler; Stefan Olaf Schönland; Anja Seckinger; Dirk Hose; Uta Bertsch; Kai Neben; Marc Steffen Raab; Jens Hillengass; Hans Salwender; Igor Wolfgang Blau; Hans-Walter Lindemann; Ingo G H Schmidt-Wolf; Christof Scheid; Mathias Haenel; Katja C Weisel; Hartmut Goldschmidt
Journal:  Blood Adv       Date:  2017-12-27

8.  Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

Authors:  Ola Landgren; Jonathan N Hofmann; Charlene M McShane; Loredana Santo; Malin Hultcrantz; Neha Korde; Sham Mailankody; Dickran Kazandjian; Kazunori Murata; Katie Thoren; Lakshmi Ramanathan; Ahmet Dogan; Even Rustad; Sydney X Lu; Theresia Akhlaghi; Sigurdur Y Kristinsson; Magnus Björkholm; Sean Devlin; Mark P Purdue; Ruth M Pfeiffer; Ingemar Turesson
Journal:  JAMA Oncol       Date:  2019-09-01       Impact factor: 31.777

9.  Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.

Authors:  John R Jones; Niels Weinhold; Cody Ashby; Brian A Walker; Chris Wardell; Charlotte Pawlyn; Leo Rasche; Lorenzo Melchor; David A Cairns; Walter M Gregory; David Johnson; Dil B Begum; Sidra Ellis; Amy L Sherborne; Gordon Cook; Martin F Kaiser; Mark T Drayson; Roger G Owen; Graham H Jackson; Faith E Davies; Mel Greaves; Gareth J Morgan
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

10.  Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.

Authors:  Ankit K Dutta; J Lynn Fink; John P Grady; Gareth J Morgan; Charles G Mullighan; Luen B To; Duncan R Hewett; Andrew C W Zannettino
Journal:  Leukemia       Date:  2018-07-25       Impact factor: 11.528
View more
  11 in total

Review 1.  Progress in the Management of Smoldering Multiple Myeloma.

Authors:  Timothy M Schmidt; Natalie S Callander
Journal:  Curr Hematol Malig Rep       Date:  2021-05-13       Impact factor: 3.952

2.  Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.

Authors:  Stephan R Bohl; Laura K Schmalbrock; Imke Bauhuf; Tatjana Meyer; Anna Dolnik; Martin Szyska; Tamara J Blätte; Sarah Knödler; Linda Röhner; Denise Miller; Miriam Kull; Christian Langer; Hartmut Döhner; Anthony Letai; Frederik Damm; Dirk Heckl; Lars Bullinger; Jan Krönke
Journal:  Blood Adv       Date:  2021-05-11

3.  Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

Authors:  Nizar J Bahlis; Rachid Baz; Simon J Harrison; Hang Quach; Shir-Jing Ho; Annette Juul Vangsted; Torben Plesner; Philippe Moreau; Simon D Gibbs; Sheryl Coppola; Xiaoqing Yang; Abdullah Al Masud; Jeremy A Ross; Orlando Bueno; Jonathan L Kaufman
Journal:  J Clin Oncol       Date:  2021-08-13       Impact factor: 44.544

Review 4.  Chromosome 1q21 abnormalities in multiple myeloma.

Authors:  Timothy M Schmidt; Rafael Fonseca; Saad Z Usmani
Journal:  Blood Cancer J       Date:  2021-04-29       Impact factor: 11.037

Review 5.  What Is New in the Treatment of Smoldering Multiple Myeloma?

Authors:  Niccolo' Bolli; Nicola Sgherza; Paola Curci; Rita Rizzi; Vanda Strafella; Mario Delia; Vito Pier Gagliardi; Antonino Neri; Luca Baldini; Francesco Albano; Pellegrino Musto
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

6.  Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.

Authors:  Ignacio Isola; Fara Brasó-Maristany; David F Moreno; Mari-Pau Mena; Aina Oliver-Calders; Laia Paré; Luis Gerardo Rodríguez-Lobato; Beatriz Martin-Antonio; María Teresa Cibeira; Joan Bladé; Laura Rosiñol; Aleix Prat; Ester Lozano; Carlos Fernández de Larrea
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

Review 7.  Genome Instability in Multiple Myeloma: Facts and Factors.

Authors:  Anna Y Aksenova; Anna S Zhuk; Artem G Lada; Irina V Zotova; Elena I Stepchenkova; Ivan I Kostroma; Sergey V Gritsaev; Youri I Pavlov
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

8.  The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma.

Authors:  Sarah Sandmann; Katharina Karsch; Peter Bartel; Rita Exeler; Tobias J Brix; Elias K Mai; Julian Varghese; Georg Lenz; Cyrus Khandanpour
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

9.  Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.

Authors:  Camille Tessier; Thomas Allard; Jean-Samuel Boudreault; Rayan Kaedbey; Vincent Éthier; Fléchère Fortin; Michel Pavic
Journal:  Curr Oncol       Date:  2021-05-26       Impact factor: 3.677

Review 10.  2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.

Authors:  Pellegrino Musto; Monika Engelhardt; Jo Caers; Niccolo' Bolli; Martin Kaiser; Niels Van de Donk; Evangelos Terpos; Annemiek Broijl; Carlos Fernández De Larrea; Francesca Gay; Hartmut Goldschmidt; Roman Hajek; Annette Juul Vangsted; Elena Zamagni; Sonja Zweegman; Michele Cavo; Meletios Dimopoulos; Hermann Einsele; Heinz Ludwig; Giovanni Barosi; Mario Boccadoro; Maria-Victoria Mateos; Pieter Sonneveld; Jesus San Miguel
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.